323 related articles for article (PubMed ID: 37833981)
21. Adjuvant and Neoadjuvant Therapies in Cutaneous Melanoma.
Ponto J; Bell RB
Oral Maxillofac Surg Clin North Am; 2022 May; 34(2):315-324. PubMed ID: 35491081
[TBL] [Abstract][Full Text] [Related]
22. Local and intralesional therapy of in-transit melanoma metastases.
Testori A; Faries MB; Thompson JF; Pennacchioli E; Deroose JP; van Geel AN; Verhoef C; Verrecchia F; Soteldo J
J Surg Oncol; 2011 Sep; 104(4):391-6. PubMed ID: 21858834
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous melanoma.
Long GV; Swetter SM; Menzies AM; Gershenwald JE; Scolyer RA
Lancet; 2023 Aug; 402(10400):485-502. PubMed ID: 37499671
[TBL] [Abstract][Full Text] [Related]
24. Survival outcomes in an older US population with advanced melanoma and central nervous system metastases: SEER-Medicare analysis.
Sadetsky N; Hernandez A; Wallick CJ; McKenna EF; Surinach A; Colburn DE
Cancer Med; 2020 Sep; 9(17):6216-6224. PubMed ID: 32667719
[TBL] [Abstract][Full Text] [Related]
25. [Study and treatment of locally advanced melanoma].
Moreno-Ramírez D; de la Cruz L; Ferrándiz L; Camacho FM
Actas Dermosifiliogr; 2009 Nov; 100(9):767-79. PubMed ID: 19889298
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and treatment of in-transit melanoma metastases.
Testori A; Ribero S; Bataille V
Eur J Surg Oncol; 2017 Mar; 43(3):544-560. PubMed ID: 27923593
[TBL] [Abstract][Full Text] [Related]
27. Melanoma.
Ingraffea A
Facial Plast Surg Clin North Am; 2013 Feb; 21(1):33-42. PubMed ID: 23369587
[TBL] [Abstract][Full Text] [Related]
28. Asymptomatic brain metastases in patients with cutaneous metastatic malignant melanoma.
Zukauskaite R; Schmidt H; Asmussen JT; Hansen O; Bastholt L
Melanoma Res; 2013 Feb; 23(1):21-6. PubMed ID: 23117880
[TBL] [Abstract][Full Text] [Related]
29. Melanoma classification and management in the era of molecular medicine.
Rashid S; Shaughnessy M; Tsao H
Dermatol Clin; 2023 Jan; 41(1):49-63. PubMed ID: 36410983
[TBL] [Abstract][Full Text] [Related]
30. Ocular melanoma metastatic to skin: the value of HMB-45 staining.
Schwartz RA; Kist JM; Thomas I; Fernández G; Cruz MA; Koziorynska EI; Lambert WC
Dermatol Surg; 2004 Jun; 30(6):942-4. PubMed ID: 15171777
[TBL] [Abstract][Full Text] [Related]
31. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
[TBL] [Abstract][Full Text] [Related]
32. Developments in Intralesional Therapy for Metastatic Melanoma.
Sloot S; Rashid OM; Sarnaik AA; Zager JS
Cancer Control; 2016 Jan; 23(1):12-20. PubMed ID: 27009452
[TBL] [Abstract][Full Text] [Related]
33. Malignant Melanoma: Diagnostic and Management Update.
Knackstedt T; Knackstedt RW; Couto R; Gastman B
Plast Reconstr Surg; 2018 Aug; 142(2):202e-216e. PubMed ID: 30045186
[TBL] [Abstract][Full Text] [Related]
34. Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
Damian DL; Saw RP; Thompson JF
J Surg Oncol; 2014 Mar; 109(4):308-13. PubMed ID: 24522938
[TBL] [Abstract][Full Text] [Related]
35. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II).
Balch CM; Soong SJ; Murad TM; Ingalls AL; Maddox WA
Ann Surg; 1981 Mar; 193(3):377-88. PubMed ID: 7212800
[TBL] [Abstract][Full Text] [Related]
36. Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
Vallet A; Oriano B; Mortier L; Dalle S; Dutriaux C; Guillot B; Leccia MT; Dalac S; Saiag P; Lacour JP; Legoupil D; De Quatrebarbes J; Brunet-Possenti F; Lesimple T; Arnault JP; Aubin F; Granel-Brocard F; Stoebner PE; Maubec E; Dreno B; Allayous C; Porcher R; Lebbé C;
JAMA Dermatol; 2019 Jun; 155(6):673-678. PubMed ID: 31042256
[TBL] [Abstract][Full Text] [Related]
37. The safety of talimogene laherparepvec for the treatment of advanced melanoma.
Gangi A; Zager JS
Expert Opin Drug Saf; 2017 Feb; 16(2):265-269. PubMed ID: 27989216
[TBL] [Abstract][Full Text] [Related]
38. Management of Stage I cutaneous melanoma.
Berdeaux DH; Moon TE; Meyskens FL
Ariz Med; 1983 Nov; 40(11):768-72. PubMed ID: 6661064
[No Abstract] [Full Text] [Related]
39. Melanoma: An update on systemic therapies.
Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
[TBL] [Abstract][Full Text] [Related]
40. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
